Greenwich LifeSciences, Inc.
GLSI
$22.23
$0.582.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.06M | 2.04M | 2.71M | 2.50M | 2.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.89M | 18.93M | 20.70M | 19.25M | 17.87M |
| Operating Income | -21.89M | -18.93M | -20.70M | -19.25M | -17.87M |
| Income Before Tax | -21.76M | -18.84M | -20.59M | -19.10M | -17.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.76 | -18.84 | -20.59 | -19.10 | -17.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.76M | -18.84M | -20.59M | -19.10M | -17.69M |
| EBIT | -21.89M | -18.93M | -20.70M | -19.25M | -17.87M |
| EBITDA | -21.89M | -18.93M | -20.70M | -19.25M | -17.87M |
| EPS Basic | -1.56 | -1.38 | -1.55 | -1.45 | -1.35 |
| Normalized Basic EPS | -0.98 | -0.86 | -0.97 | -0.90 | -0.84 |
| EPS Diluted | -1.56 | -1.38 | -1.55 | -1.45 | -1.35 |
| Normalized Diluted EPS | -0.98 | -0.86 | -0.97 | -0.90 | -0.84 |
| Average Basic Shares Outstanding | 55.53M | 54.13M | 53.33M | 52.83M | 52.37M |
| Average Diluted Shares Outstanding | 55.53M | 54.13M | 53.33M | 52.83M | 52.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |